Cargando…

Assessment of concentrations of sTRAIL ligand and its receptors sTRAIL-R1 and sTRAIL-R2 – markers monitoring the course of the extrinsic pathway of apoptosis induction: potential application in ovarian cancer diagnostics

INTRODUCTION: TNF-related apoptosis-inducing ligand (TRAIL) together with its receptors are involved in activation of the extrinsic pathway of apoptosis. Due to the special role of the apoptosis pathway in pathogenesis of ovarian cancers, the aim of the study was to assess concentrations of sTRAIL,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mielczarek-Palacz, Aleksandra, Sikora, Justyna, Kondera-Anasz, Zdzisława
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2015
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5420616/ https://www.ncbi.nlm.nih.gov/pubmed/28507579 http://dx.doi.org/10.5114/aoms.2015.53144

Ejemplares similares

Changes in the Concentration of Markers Participating in the Regulation of the Apoptosis Receptor Pathway Involving Soluble Tumour Necrosis Factor Ligand Inducing Apoptosis (sTRAIL) and Osteoprotegerin (OPG) in the Serum of Women with Ovarian Cancer—Participation in Pathogenesis or a Possible Clinical Use?
por: Mielczarek-Palacz, Aleksandra, et al.
Publicado: (2020)

sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment
por: Huang, Ying, et al.
Publicado: (2017)

Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer
por: Bisgin, Atil, et al.
Publicado: (2012)

Association of circulating sTRAIL and high-sensitivity CRP with type 2 diabetic nephropathy and foot ulcers
por: Arık, Hasan Onur, et al.
Publicado: (2013)

Systemically administered AAV9-sTRAIL combats invasive glioblastoma in a patient-derived orthotopic xenograft model
por: Crommentuijn, Matheus HW, et al.
Publicado: (2016)

Engineered sTRAIL-armed MSCs overcome STING deficiency to enhance the therapeutic efficacy of radiotherapy for immune checkpoint blockade
por: Huang, Kevin Chih-Yang, et al.
Publicado: (2022)

Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells
por: Bremer, Edwin, et al.
Publicado: (2008)

Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects
por: Yu, R, et al.
Publicado: (2013)

Anti-Cancer Effect of Neural Stem Cells Transfected with Carboxylesterase and sTRAIL Genes in Animals with Brain Lesions of Lung Cancer
por: Kim, Jung Hak, et al.
Publicado: (2023)

The inhibitory effect of human umbilical cord mesenchymal stem cells expressing anti-HAAH scFv-sTRAIL fusion protein on glioma
por: Xue, Tian, et al.
Publicado: (2022)

Higher serum levels of tumour necrosis factor and its soluble receptors are associated with ovarian tumours
por: Mielczarek-Palacz, Aleksandra, et al.
Publicado: (2012)

Health outcomes, education, healthcare delivery and quality – 3038: The relation of sTRAIL levels and quality of life in omalizumab using severe persistent allergic asthma patients
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

Basic and clinical immunology – 3031. The correlation between serum protemics patterns of sTRAIL and CXCL8 with FDG-PET/CT findings in bevacizumab treated colon cancers
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

Immunotherapy – 2071. Strail levels decreased after allergen-subcutaneous specific immunotherapy
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

Effect of Th1/Th2 cytokine administration on proinflammatory SKOV-3 cell activation
por: Mielczarek-Palacz, Aleksandra, et al.
Publicado: (2015)

Participation of Selected Soluble BMP-2 and BMP-7 Bone Morphogenetic Proteins and Their Soluble Type I ALK-1 and Type II BMPR2 Receptors in Formation and Development of Endometriosis
por: Janusz, Joanna, et al.
Publicado: (2021)

The role of complement components C1q, MBL and C1 inhibitor in pathogenesis of endometriosis
por: Sikora, Justyna, et al.
Publicado: (2018)

N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death
por: Dufour, Florent, et al.
Publicado: (2017)

The role of galectins-1, 3, 7, 8 and 9 as potential diagnostic and therapeutic markers in ovarian cancer
por: Mielczarek-Palacz, Aleksandra, et al.
Publicado: (2022)

TRAIL-R1 and TRAIL-R2 Mediate TRAIL-Dependent Apoptosis in Activated Primary Human B Lymphocytes
por: Staniek, Julian, et al.
Publicado: (2019)

Mechanisims of asthma and allergic disease - 1088. Increased serum strail level in newly diagnosed stave-iv lung adenocarcinoma but not sqamous cell carcinoma, is correlated with age and smoking
por: Kargi, Aysegul, et al.
Publicado: (2013)

Enacting Phenomenological Gestalts in Ultra-Trail Running: An Inductive Analysis of Trail Runners’ Courses of Experience
por: Rochat, Nadège, et al.
Publicado: (2018)

N-glycosylation of mouse TRAIL-R restrains TRAIL-induced apoptosis
por: Estornes, Yann, et al.
Publicado: (2018)

TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill
por: Mohr, Andrea, et al.
Publicado: (2015)

TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress
por: Dufour, Florent, et al.
Publicado: (2016)

Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells
por: Trivedi, Rachana, et al.
Publicado: (2015)

Compartmentalization of TNF-related apoptosis-inducing ligand (TRAIL) death receptor functions: emerging role of nuclear TRAIL-R2
por: Bertsch, U, et al.
Publicado: (2014)

Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family
por: Degli-Esposti, Mariapia A., et al.
Publicado: (1997)

Targeting Death Receptor TRAIL-R2 by Chalcones for TRAIL-Induced Apoptosis in Cancer Cells
por: Szliszka, Ewelina, et al.
Publicado: (2012)

TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells
por: Tuthill, Mark H, et al.
Publicado: (2014)

TRAIL-β and TRAIL-γ: two novel splice variants of the human TNF-related apoptosis-inducing ligand (TRAIL) without apoptotic potential
por: Krieg, A, et al.
Publicado: (2003)

TRAIL/TRAIL Receptor System and Susceptibility to Multiple Sclerosis
por: López-Gómez, Carlos, et al.
Publicado: (2011)

TRAIL combinations: The new ‘trail’ for cancer therapy (Review)
por: REFAAT, ALAA, et al.
Publicado: (2014)

Crossed TRAILs
por: Wells, William A.
Publicado: (2002)

The white trail /
por: Dafydd, Fflur
Publicado: (2011)

The information trail
por: Berman, Carol
Publicado: (2016)

John Trail
Publicado: (1889)

Endogenous TRAIL-R4 critically impacts apoptotic and non-apoptotic TRAIL-induced signaling in cancer cells
por: Rambow, Anna-Christina, et al.
Publicado: (2022)

Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody
por: Martini, Silvia, et al.
Publicado: (2020)

The regulation of combined treatment-induced cell death with recombinant TRAIL and bortezomib through TRAIL signaling in TRAIL-resistant cells
por: Ryu, Sunhyo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ud53jk8ksvj026f9m53c4uohcf